tVNS for Prader-Willi syndrome

The short version

Prader-Willi syndrome is a rare genetic condition that affects roughly one in every 15,000 to 25,000 births. Among its most difficult features are the temper outbursts: explosive emotional episodes that can dominate daily life for the person with PWS and everyone around them. There are no approved drugs that target this.

tVNS is a small device with an electrode worn in the ear that delivers gentle electrical pulses to a branch of the vagus nerve. In the one published study of tVNS specifically for PWS, four out of five adults with the condition experienced significant reductions in the frequency and severity of temper outbursts after nine months of daily use. This is a small study. It is not blinded. But it is the most encouraging evidence available for a problem that currently has very few answers.

The tVNS device is one of very few medical devices with a specific regulatory approval for Prader-Willi syndrome. It is manufactured in Germany and distributed in the UK by Anatomical Concepts UK.

What we are trying to solve

Prader-Willi syndrome is caused by the absence of certain genes on chromosome 15. It follows a distinctive pattern. In infancy, the main problems are low muscle tone and feeding difficulties. In childhood and through adulthood, the picture shifts. The hallmark is hyperphagia: a relentless, neurologically driven hunger that, without constant environmental management, leads to life-threatening obesity. But the feature that many families describe as the most distressing on a day-to-day basis is the emotional dysregulation.

Temper outbursts in PWS are not ordinary tantrums. They are intense, often explosive episodes that can involve verbal and physical aggression, distress, and self-injury. They can be triggered by changes in routine, thwarted expectations, or sometimes nothing obviously identifiable. They are a leading cause of placement breakdowns, restricted community access, and reduced quality of life for individuals and their families.

Here is the problem that frames everything else. There is no approved pharmacological treatment for the core features of PWS. For hyperphagia, the main intervention is environmental: locked kitchens, structured meal plans, constant supervision. For the temper outbursts, some clinicians use SSRIs or aripiprazole with variable success, but these are not targeted treatments and they were not designed for this population. The clinical toolbox is close to empty.

This is why there is genuine interest in neuromodulation. The vagus nerve is connected to the brain circuits that regulate emotion, autonomic balance, and inflammation, all of which are disrupted in PWS. The question is whether stimulating it can move the needle.

How it works, in plain English

The vagus nerve connects the brainstem to most of the body's major organs and carries signals in both directions. A small branch of it surfaces in the outer ear on a ridge called the cymba conchae. The tVNS device clips into the ear and delivers gentle electrical pulses to this branch.

Those pulses travel up to the brainstem and from there to brain regions involved in emotional regulation. The locus coeruleus, which produces norepinephrine, plays a role in arousal, attention, and how the brain responds to unexpected or frustrating events. The amygdala, which processes threat and emotion, has direct connections to the vagal pathway. The prefrontal cortex, which helps regulate emotional responses, receives input from vagal relay centres.

By stimulating the vagus nerve, tVNS appears to shift the nervous system toward a calmer, more regulated state. In the PWS studies, this manifested as fewer and less severe temper outbursts. The researchers also measured heart rate variability (a marker of vagal tone) and found that tVNS increased it, confirming that the device was having a measurable physiological effect on the autonomic nervous system.

It is worth noting what tVNS has not been shown to do in PWS. The earlier study using an implanted vagus nerve stimulator did not achieve clear improvements in hyperphagia. The appetite mechanism is biologically plausible (the vagus nerve is central to gut-brain signalling), but it has not been demonstrated clinically in this population. At present, the evidence supports tVNS for behavioural regulation, not for appetite control.

What the evidence shows

Let us be direct about the state of the evidence. The published research on tVNS specifically for PWS comes from a single research group at the University of Cambridge. The total sample size is five adults. This is the honest picture.

Five adults with PWS (all with the paternal deletion subtype, aged 22 to 41) used tVNS at home for 12 months, 4 hours daily.
Four out of five experienced statistically significant reductions in outburst frequency and severity.
The improvements emerged after approximately nine months. This is a long time, and it tells you something about the patience this treatment requires.
When the daily stimulation was reduced from 4 hours to 2 hours, the outbursts returned in the responders. This dose-response finding strengthens the case that the effect was real and not a placebo response.
All four responders chose to continue the treatment after the study ended. At informal follow-up years later, they reported continuing benefits.
In the small published study, side effects were mild: one person experienced skin irritation at the electrode site, which resolved. The Instructions for Use list the full range of possible effects, including local skin reactions and, as with any vagus nerve therapy, effects such as dizziness, nausea, or ear discomfort.

What the evidence does not show:

There is no blinded, controlled trial yet. The study was non-blind, meaning both the participants and the researchers knew who was receiving treatment. This matters because some of the improvement could, in principle, be explained by the attention and structure of being in a study.
All participants had the paternal deletion subtype of PWS. Whether tVNS works equally well for people with uniparental disomy or imprinting defect subtypes is unknown.
The published evidence covers adults aged 22 to 41. Effects in children and adolescents are untested in PWS specifically.

A larger trial is underway. The VNS4PWS Phase 3 trial is a randomised, double-blind, dose-ranging trial that is currently recruiting participants aged 10 to 40 with genetically confirmed PWS. When it reports, it will be the first blinded, controlled data for tVNS in this population. This is exactly the kind of evidence the field needs.

What to expect

The practical side of using tVNS for PWS looks like this.

A carer manages the device. In most cases, the person with PWS will not operate the device independently. A carer positions the electrode, sets the intensity, and monitors use.
The device is used for 4 hours daily. This is based on the protocol used in the Cambridge study. The time can be split into sessions and used during activities like watching television, listening to music, or resting. The routine aspect may actually suit many people with PWS, who tend to prefer predictable structure.
You keep a behavioural diary. Record the frequency, duration, and severity of temper outbursts from at least four weeks before starting. This is how you and the clinical team judge whether the treatment is working.
You wait. And you keep waiting. The benefit in the published study emerged after about nine months. This is a long commitment, and it asks a lot of families. We think it is better to set this expectation clearly at the start than to create disappointment at three months.
You review regularly. At 3, 6, 9, and 12 months, review the diary with the clinical team. If measurable improvement is appearing, continue. If not after 12 months, it may be time to reconsider.

Introducing the device gradually is important. A new daily routine can be challenging for someone with PWS. Start with short sessions and build up over one to two weeks. A clear visual schedule can help.

Who it is not for

The Instructions for Use state that tVNS is intended for adults aged 18 and over. It should not be used by people who:

are pregnant
have an active implant, such as a cochlear implant, an implanted vagus nerve stimulator, or a cardiac pacemaker
have a cerebral shunt (for example, for hydrocephalus)
have sore or broken skin where the electrode would sit (monitor for skin picking, which is common in PWS)

If there is a heart rhythm problem, talk to a doctor first. Sensory sensitivity is common in PWS, so the current intensity should be set carefully, starting low and increasing gradually until the person reports a comfortable tingling. tVNS should be used under medical supervision.

Common questions

Will tVNS reduce the food-seeking behaviour? Based on the current evidence, no. The implanted VNS study in PWS did not achieve clear improvements in hyperphagia, and the transcutaneous study was designed around temper outbursts, not appetite. The vagus nerve is involved in appetite signalling, so there is a biological reason to hope, but the clinical evidence is not there yet.

How long do we have to use it before we can tell if it is working? The published study saw meaningful improvements at around nine months. That is longer than most other tVNS indications. We recommend committing to at least 9 to 12 months of consistent daily use before judging.

Is the evidence strong enough to try? That depends on your situation. The evidence comes from a small, unblinded study with encouraging but preliminary results. For a condition with almost no effective treatments for temper outbursts, many families and clinicians consider a safe, non-invasive option with preliminary positive signals to be worth trying. The decision is yours and your clinical team's.

Can children use it? The tVNS E Instructions for Use state the device is intended for adults aged 18 and over, and the published PWS evidence is in adults (aged 22 to 41). An ongoing trial includes younger participants from age 10, but using the device in a child would fall outside its current intended use and should only be considered with a specialist who knows the condition.

Does my child need a genetic diagnosis first? The published evidence and the ongoing trial both require genetically confirmed PWS. Without a confirmed genetic diagnosis, the evidence base does not directly apply.

What to do next

Talk to your specialist. PWS is usually managed by a multidisciplinary team. Raise tVNS with them and ask whether they think it is worth trying. If they want more information, we can speak to them directly.
Read the clinicians' page for the full evidence, stimulation parameters, and study details.
Contact us. If you are a family living with PWS and want to talk through whether tVNS might help, call or email. We understand that families in this situation are often exhausted and have heard too many promises. We will be honest about what the evidence does and does not show.

Contact Anatomical Concepts UK

For clinicians: the full evidence page

How to access tVNS

This page is for information only. It is not medical advice. Any decision about tVNS should be made with your clinician, who knows your full medical history.

tVNS is a Class IIa medical device manufactured by tVNS Technologies GmbH, Germany. Distributed in the UK by Anatomical Concepts UK Ltd.